Startup Microlin Aims for microRNA Drugs, Diagnostics with OSU IP in Hand | GenomeWeb

Having secured the rights to a portfolio of nearly 100 issued and pending microRNA-related patents from Ohio State University, startup Microlin Bio has set its sights on developing both diagnostics and therapeutics based on the non-coding RNAs, with its first product on track to hit the market next year.

Late last month, Microlin announced that it had picked up access to the OSU intellectual property, which relates to miRNAs and their role in cancers including prostate, ovarian, colon, and lung, in addition to a novel lipid nanoparticle delivery technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.